Showing results (181-190 of 432) with videos related to
Sort By:
Pageof 44
Expert Review of Anticancer Therapy|August 8, 2020
The emerging role of PARP inhibitors in prostate cancerMarco Stellato, Valentina Guadalupi, Pierangela Sepe, et al.Plos One|September 13, 2018
Genetic ablation of interacting with Spt6 (Iws1) causes early embryonic lethalityArturo Orlacchio, Aaron E Stark, Claudia Foray, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 28, 2016
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumorsGiuseppe Lo Russo, Sara Pusceddu, Natalie Prinzi, et al.Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 5, 2016
Treatment of lung large cell neuroendocrine carcinomaGiuseppe Lo Russo, Sara Pusceddu, Claudia Proto, et al.Biomedicines|October 27, 2022
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell CarcinomaMartina Catalano, Ugo De Giorgi, Marco Maruzzo, et al.American Journal of Clinical Oncology|September 5, 2020
Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study)Pierangela Sepe, Antonia Martinetti, Alessia Mennitto, et al.Cancers|April 10, 2019
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-AnalysisSara Pusceddu, Michele Ghidini, Martina Torchio, et al.Journal of Clinical Medicine|February 15, 2022
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective StudyAngela Dalia Ricci, Sara Pusceddu, Francesco Panzuto, et al.European Journal of Nuclear Medicine and Molecular Imaging|September 5, 2024
The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATEMarco Maccauro, Mariarosaria Cuomo, Matteo Bauckneht, et al.European Urology Oncology|July 24, 2019
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?Melissa Bersanelli, Roberto Iacovelli, Sebastiano Buti, et al.Pageof 44